ARTICLES BY KATIE MCCARTHY
-
![rare-disease]( "Human Gene Therapy For Rare Disease — Examining FDA’s New Draft Guidance")
Human Gene Therapy For Rare Disease — Examining FDA’s New Draft Guidance7/30/2018The FDA recently issued for public comment six draft guidance documents. This is the fourth article in a series and will discuss the guidance Human Gene Therapy for Rare Disease.
Katie McCarthy
Katie McCarthy is VP of regulatory affairs in the Drug and Biological Products group at Greenleaf Health, Inc. She specializes in scientific and regulatory issues affecting pharmaceutical and biotechnology companies. You can reach her at katie.mccarthy@greenleafhealthllc.com.
This website uses cookies to ensure you get the best experience on our website. Learn more